CYTOKINETICS (CYTK) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$62.91
+1.5% on the day
+4.3% over 12 months
52-week range $54.76 – $87.26
Share price and insider trades
CYTK closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$51.8M
Insiders buying0
Insiders selling10
CYTOKINETICS insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 10 sold $51.8M of CYTK stock on the open market.
Get emailed when insiders cluster-buy stocks like CYTK
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
CYTK insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $215K | 1 |
| Q3 2026 | — | 0 | $15.9M | 21 |
| Q2 2026 | — | 0 | $16.9M | 25 |
| Q1 2026 | — | 0 | $9.1M | 22 |
| Q4 2025 | — | 0 | $10.6M | 20 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.3×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 CYTOKINETICS INC insiders reported open-market purchases totaling $0, while 10 insiders reported sales totaling $51.8M. 79 of 89 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 6SEC | Fady Ibraham MalikEvp Research & Development | Sell Plan | 3,500153,902 held (−2%) | $61.38 | $215K | +2.5% | — |
| Sep 28SEC | Robert I BlumCEO, President | Sell Plan | 7,500278,544 held (−3%) | $65.46 | $491K | -3.9% | — |
| Sep 22SEC | Fady Ibraham MalikEvp Research & Development | Sell Plan | 3,500153,902 held (−2%) | $68.29 | $239K | -7.9% | — |
| Sep 15SEC | Robert I BlumCEO, President | Sell Plan | 97,926 | $69.33 | $6.8M | -9.3% | — |
| Sep 15SEC | Robert I BlumCEO, President | Sell Plan | 7,500377,820 held (−2%) | $73.44 | $551K | -14.3% | — |
| Sep 15SEC | Robert E LandryDirector | Sell Plan | 1,0008,184 held (−11%) | $72.13 | $72K | -12.8% | — |
| Sep 11SEC | Robert E LandryDirector | Sell Plan | 1,0009,184 held (−10%) | $74.66 | $75K | -15.7% | — |
| Sep 8SEC | Fady Ibraham MalikEvp Research & Development | Sell Plan | 3,500153,902 held (−2%) | $75.46 | $264K | -16.6% | — |
| Sep 1SEC | B Lynne ParshallDirector | Sell Plan | 5,00010,784 held (−32%) | $71.48 | $357K | -12.0% | — |
| Aug 31SEC | Andrew CallosEvp, Chief Commercial Officer | Sell Plan | 10,00058,555 held (−15%) | $70.24 | $702K | -10.4% | — |
| Aug 31SEC | Robert I BlumCEO, President | Sell Plan | 7,500377,820 held (−2%) | $70.24 | $527K | -10.4% | — |
| Aug 18SEC | Fady Ibraham MalikEvp Research & Development | Sell Plan | 3,500153,902 held (−2%) | $75.82 | $265K | -17.0% | — |
| Aug 10SEC | Robert I BlumCEO, President | Sell Plan | 7,500377,820 held (−2%) | $76.76 | $576K | -18.0% | — |
| Jul 30SEC | Andrew CallosEvp, Chief Commercial Officer | Sell Plan | 14,00058,555 held (−19%) | $79.88 | $1.1M | -21.2% | — |
| Jul 27SEC | Robert I BlumCEO, President | Sell Plan | 7,500377,820 held (−2%) | $80.87 | $607K | -22.2% | — |
| Jul 23SEC | Fady Ibraham MalikEvp Research & Development | Sell Plan | 3,500153,902 held (−2%) | $80.59 | $282K | -21.9% | — |
| Jul 14SEC | Robert I BlumCEO, President | Sell Plan | 7,490377,820 held (−2%) | $82.02 | $614K | -23.3% | — |
| Jul 14SEC | Robert I BlumCEO, President | Sell Plan | 10377,820 held (−0%) | $82.02 | $820 | -23.3% | — |
| Jul 7SEC | Fady Ibraham MalikEvp Research & Development | Sell Plan | 3,500153,902 held (−2%) | $86.62 | $303K | -27.4% | — |
| Jul 2SEC | Andrew CallosEvp, Chief Commercial Officer | Sell Plan | 15,00058,555 held (−20%) | $85.80 | $1.3M | -26.7% | — |
| Jul 2SEC | Robert I BlumCEO, President | Sell Plan | 7,500377,830 held (−2%) | $84.92 | $637K | -25.9% | — |
| Jul 2SEC | Sung LeeCFO | Sell Plan | 1,11263,221 held (−2%) | $87.79 | $98K | -28.3% | — |
| Jun 29SEC | Sung LeeCFO | Sell Plan | 38,73063,221 held (−38%) | $82.30 | $3.2M | -23.6% | — |
| Jun 29SEC | Sung LeeCFO | Sell Plan | 3,13463,221 held (−5%) | $85.00 | $266K | -26.0% | — |
| Jun 23SEC | Fady Ibraham MalikEvp Research & Development | Sell Plan | 3,500153,902 held (−2%) | $79.51 | $278K | -20.9% | — |
| Jun 15SEC | Robert I BlumCEO, President | Sell Plan | 7,500385,330 held (−2%) | $70.46 | $528K | -10.7% | — |
| Jun 9SEC | Fady Ibraham MalikEvp Research & Development | Sell Plan | 3,500153,902 held (−2%) | $67.98 | $238K | -7.5% | — |
| Jun 1SEC | Andrew CallosEvp, Chief Commercial Officer | Sell Plan | 15,00058,555 held (−20%) | $74.08 | $1.1M | -15.1% | — |
| Jun 1SEC | B Lynne ParshallDirector | Sell Plan | 5,00015,784 held (−24%) | $74.08 | $370K | -15.1% | — |
| Jun 1SEC | Edward M. Md KayeDirector | Sell Plan | 2,93310,283 held (−22%) | $76.09 | $223K | -17.3% | — |
| May 28SEC | Robert I BlumCEO, President | Sell Plan | 7,500392,830 held (−2%) | $77.21 | $579K | -18.5% | — |
| May 20SEC | Fady Ibraham MalikEvp Research & Development | Sell Plan | 3,500153,902 held (−2%) | $75.69 | $265K | -16.9% | — |
| May 14SEC | Robert I BlumCEO, President | Sell Plan | 7,500400,330 held (−2%) | $77.92 | $584K | -19.3% | — |
| May 5SEC | Sung LeeCFO | Sell Plan | 23,90663,221 held (−27%) | $76.87 | $1.8M | -18.2% | — |
| May 5SEC | John T HendersonDirector | Sell Plan | 20,00075,237 held (−21%) | $75.97 | $1.5M | -17.2% | — |
| May 5SEC | Andrew CallosEvp, Chief Commercial Officer | Sell Plan | 11,33358,555 held (−16%) | $77.25 | $875K | -18.6% | — |
| May 5SEC | Wendell WierengaDirector | Sell Plan | 4,03232,637 held (−11%) | $75.00 | $302K | -16.1% | — |
| May 5SEC | Fady Ibraham MalikEvp Research & Development | Sell Plan | 3,500153,902 held (−2%) | $77.37 | $271K | -18.7% | — |
| May 4SEC | Andrew CallosEvp, Chief Commercial Officer | Sell Plan | 15,85758,555 held (−21%) | $65.00 | $1.0M | -3.2% | — |
| Apr 30SEC | Andrew CallosEvp, Chief Commercial Officer | Sell Plan | 15,00058,555 held (−20%) | $63.26 | $949K | -0.6% | — |
| Apr 29SEC | Robert I BlumCEO, President | Sell Plan | 7,500407,830 held (−2%) | $59.62 | $447K | +5.5% | — |
| Apr 21SEC | Fady Ibraham MalikEvp Research & Development | Sell Plan | 3,500153,902 held (−2%) | $65.69 | $230K | -4.2% | — |
| Apr 15SEC | Andrew CallosEvp, Chief Commercial Officer | Sell Plan | 7,44958,555 held (−11%) | $66.02 | $492K | -4.7% | — |
| Apr 15SEC | Robert I BlumCEO, President | Sell Plan | 7,500415,330 held (−2%) | $65.38 | $490K | -3.8% | — |
| Apr 8SEC | Fady Ibraham MalikEvp Research & Development | Sell Plan | 3,500153,902 held (−2%) | $65.21 | $228K | -3.5% | — |
| Apr 8SEC | Fady Ibraham MalikEvp Research & Development | Sell Plan | 1,000153,902 held (−1%) | $64.75 | $65K | -2.8% | — |
| Apr 1SEC | Robert I BlumCEO, President | Sell Plan | 7,500422,830 held (−2%) | $66.63 | $500K | -5.6% | — |
| Mar 31SEC | Andrew CallosEvp, Chief Commercial Officer | Sell Plan | 3,63966,004 held (−5%) | $65.00 | $237K | -3.2% | — |
| Mar 18SEC | Robert I BlumCEO, President | Sell | 23,928430,330 held (−5%) | $62.15 | $1.5M | +1.2% | — |
| Mar 18SEC | Robert I BlumCEO, President | Sell | 12,673454,258 held (−3%) | $62.15 | $788K | +1.2% | — |
| Mar 18SEC | Fady Ibraham MalikEvp Research & Development | Sell | 7,636158,299 held (−5%) | $62.15 | $475K | +1.2% | — |
| Mar 18SEC | Andrew CallosEvp, Chief Commercial Officer | Sell | 5,62674,489 held (−7%) | $62.15 | $350K | +1.2% | — |
| Mar 18SEC | Sung LeeCFO | Sell | 4,93587,127 held (−5%) | $62.15 | $307K | +1.2% | — |
| Mar 18SEC | Fady Ibraham MalikEvp Research & Development | Sell | 4,397153,902 held (−3%) | $62.15 | $273K | +1.2% | — |
| Mar 18SEC | Andrew CallosEvp, Chief Commercial Officer | Sell | 2,91671,573 held (−4%) | $62.15 | $181K | +1.2% | — |
| Mar 18SEC | Andrew CallosEvp, Chief Commercial Officer | Sell Plan | 1,93078,185 held (−2%) | $62.07 | $120K | +1.4% | — |
| Mar 16SEC | Andrew CallosEvp, Chief Commercial Officer | Sell Plan | 1,70946,149 held (−4%) | $61.03 | $104K | +3.1% | — |
| Mar 10SEC | Robert I BlumCEO, President | Sell | 7,931391,673 held (−2%) | $60.72 | $482K | +3.6% | — |
| Mar 10SEC | Fady Ibraham MalikEvp Research & Development | Sell | 2,907138,629 held (−2%) | $60.72 | $177K | +3.6% | — |
| Mar 10SEC | Andrew CallosEvp, Chief Commercial Officer | Sell | 2,58247,858 held (−5%) | $60.72 | $157K | +3.6% | — |
| Mar 5SEC | Andrew CallosEvp, Chief Commercial Officer | Sell Plan | 15,00061,440 held (−20%) | $61.87 | $928K | +1.7% | — |
| Mar 5SEC | Andrew CallosEvp, Chief Commercial Officer | Sell Plan | 11,00050,440 held (−18%) | $61.88 | $681K | +1.7% | — |
| Mar 2SEC | B Lynne ParshallDirector | Sell Plan | 5,00017,933 held (−22%) | $61.21 | $306K | +2.8% | — |
| Mar 2SEC | Andrew CallosEvp, Chief Commercial Officer | Sell Plan | 88650,440 held (−2%) | $61.62 | $55K | +2.1% | — |
| Feb 5SEC | Andrew CallosEvp, Chief Commercial Officer | Sell Plan | 15,00050,440 held (−23%) | $61.93 | $929K | +1.6% | — |
| Feb 2SEC | Andrew CallosEvp, Chief Commercial Officer | Sell Plan | 88650,440 held (−2%) | $62.10 | $55K | +1.3% | — |
| Jan 5SEC | Andrew CallosEvp, Chief Commercial Officer | Sell Plan | 15,00050,440 held (−23%) | $60.28 | $904K | +4.4% | — |
| Jan 2SEC | Andrew CallosEvp, Chief Commercial Officer | Sell Plan | 91350,440 held (−2%) | $62.09 | $57K | +1.3% | — |
| Jan 2SEC | Andrew CallosEvp, Chief Commercial Officer | Sell Plan | 88550,440 held (−2%) | $63.16 | $56K | -0.4% | — |
| Dec 30SEC | Andrew CallosEvp, Chief Commercial Officer | Sell Plan | 1,80951,353 held (−3%) | $62.44 | $113K | +0.8% | — |
| Dec 23SEC | Wendell WierengaDirector | Sell Plan | 20,00032,444 held (−38%) | $66.14 | $1.3M | -4.9% | — |
| Dec 16SEC | Fady Ibraham MalikEvp Research & Development | Sell Plan | 2,200138,552 held (−2%) | $61.24 | $135K | +2.7% | — |
| Dec 8SEC | Andrew CallosEvp, Chief Commercial Officer | Sell Plan | 1,04250,660 held (−2%) | $65.96 | $69K | -4.6% | — |
| Dec 5SEC | Andrew CallosEvp, Chief Commercial Officer | Sell Plan | 52,48650,660 held (−51%) | $65.95 | $3.5M | -4.6% | — |
| Dec 2SEC | Edward M. Md KayeDirector | Sell Plan | 28,0649,977 held (−74%) | $66.72 | $1.9M | -5.7% | — |
| Dec 2SEC | John T HendersonDirector | Sell Plan | 8,75074,578 held (−11%) | $63.90 | $559K | -1.5% | — |
| Dec 2SEC | Robert Arthur HarringtonDirector | Sell Plan | 2,15018,542 held (−10%) | $66.80 | $144K | -5.8% | — |
| Dec 2SEC | Fady Ibraham MalikEvp Research & Development | Sell Plan | 2,200140,610 held (−2%) | $63.89 | $141K | -1.5% | — |
| Nov 19SEC | B Lynne ParshallDirector | Sell Plan | 5,00022,933 held (−18%) | $64.73 | $324K | -2.8% | — |
| Nov 18SEC | Fady Ibraham MalikEvp Research & Development | Sell Plan | 2,200140,610 held (−2%) | $66.45 | $146K | -5.3% | — |
| Nov 12SEC | Edward M. Md KayeDirector | Sell Plan | 5,1759,977 held (−34%) | $65.08 | $337K | -3.3% | — |
| Nov 4SEC | Fady Ibraham MalikEvp Research & Development | Sell Plan | 2,295140,610 held (−2%) | $59.55 | $137K | +5.6% | — |
| Oct 30SEC | Robert I BlumCEO, President | Sell Plan | 5,000358,108 held (−1%) | $62.86 | $314K | +0.1% | — |
| Oct 27SEC | Wendell WierengaDirector | Sell Plan | 4,37532,444 held (−12%) | $58.68 | $257K | +7.2% | — |
| Oct 21SEC | Fady Ibraham MalikEvp Research & Development | Sell Plan | 2,105140,610 held (−1%) | $58.22 | $123K | +8.1% | — |
| Oct 16SEC | Robert I BlumCEO, President | Sell Plan | 5,000363,108 held (−1%) | $60.03 | $300K | +4.8% | — |
| Oct 7SEC | Fady Ibraham MalikEvp Research & Development | Sell Plan | 2,000140,610 held (−1%) | $60.56 | $121K | +3.9% | — |
| Oct 6SEC | Edward M. Md KayeDirector | Sell Plan | 6,7579,778 held (−41%) | $60.00 | $405K | +4.8% | — |
| Oct 1SEC | Robert I BlumCEO, President | Sell Plan | 5,000368,108 held (−1%) | $55.05 | $275K | +14.3% | — |
Insiders at CYTOKINETICS INC
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Robert I BlumCEO, President | — | $17.6M | Sep 28, 2026 | — |
| Andrew CallosEvp, Chief Commercial Officer | — | $16.0M | Aug 31, 2026 | — |
| Sung LeeCFO | — | $5.7M | Jul 2, 2026 | — |
| Fady Ibraham MalikEvp Research & Development | — | $4.9M | Oct 6, 2026 | — |
| Edward M. Md KayeDirector | — | $2.8M | Jun 1, 2026 | — |
| John T HendersonDirector | — | $2.1M | May 5, 2026 | — |
| Wendell WierengaDirector | — | $1.9M | May 5, 2026 | — |
| B Lynne ParshallDirector | — | $1.4M | Sep 1, 2026 | — |
| Robert E LandryDirector | — | $147K | Sep 15, 2026 | — |
| Robert Arthur HarringtonDirector | — | $144K | Dec 2, 2025 | — |
CYTK stock: common questions
Are CYTOKINETICS INC insiders buying CYTK stock?
In the past 12 months, 0 insiders reported open-market purchases of CYTK worth $0.
Are CYTOKINETICS INC insiders selling CYTK stock?
10 insiders reported sales worth $51.8M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is CYTK's 52-week range?
Over the past year CYTK has traded between $54.76 and $87.26. It last closed at $62.91 on Oct 9, 2026.